Infliximab as first-line therapy in severe pediatric Crohn disease.
de Ridder
Lissy
L
Emma Children's Hospital/Academic Medical Center, G8-205, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. l.deridder@amc.uva.nl
Benninga
Marc A
MA
Taminiau
Jan A J M
JA
Hommes
Daniël W
DW
D015746:Abdominal Pain; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use; D001799:Blood Sedimentation; D002648:Child; D003106:Colon / Q000473:pathology; D003113:Colonoscopy; D003424:Crohn Disease / Q000175:diagnosis* / Q000188:drug therapy*; D003967:Diarrhea; D004384:Duodenoscopy; D004386:Duodenum / Q000473:pathology; D004947:Esophagus / Q000473:pathology; D005260:Female; D005773:Gastroscopy; D006801:Humans; D007082:Ileum / Q000473:pathology; D000069285:Infliximab; D007413:Intestinal Mucosa / Q000473:pathology; D012074:Remission Induction; D012720:Severity of Illness Index; D012812:Sigmoidoscopy; D013270:Stomach / Q000473:pathology; D015431:Weight Loss
D000911:Antibodies, Monoclonal; D000069285:Infliximab; D001379:Azathioprine